Please assess the completion status of the following clinical trial:

Trial Title: Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women not of childbearing potential (WNOCBP) and males. Women must have documented proof they are not of childbearing potential~* BMI of 20.0 to 38.0 kg/m2, inclusive~* Hepatic subjects classified as Child-Pugh mild (Class A) or Child-Pugh moderate (Class B) who have had no significant change to disease status in past 6 months and are on stable treatment regimen~* Healthy subjects must not have clinically significant deviations from normal in medical history, physical exam, ECGs, vital signs or clinical lab values~Exclusion Criteria:~* Evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent unexplained bruising or thrombus formation~* Use of corticosteroids, nonsteroidal anti-inflammatory compounds, aspirin or other antiplatelet agents or anticoagulants within 2 weeks of dosing~* Healthy subjects must not have used tobacco or have a history of drug or alcohol abuse within the last 6 months~* Subjects must not have a current or recent (within 3 months) GI disease that increases participant risk of GI bleeding or interferes with absorption of the study drug~Other protocol defined inclusion and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Mild Hepatic Subjects (Type: EXPERIMENTAL): Subjects are given a single dose of BMS-986177
- Moderate Hepatic Subjects (Type: EXPERIMENTAL): Subjects are given a single dose of BMS-986177
- Healthy Match Subjects (Type: EXPERIMENTAL): Subjects are given a single dose of BMS-986177

Based on this trial design, predict the completion outcome and termination type (if applicable).